-transparent.png){kind=logo}
The efficacy of a new third-generation cephalosporin, cefixime, in the treatment of acute otitis media resulting from infection with ampicillin-resistant, beta-lactamase-producing nontypable Haemophilus influenzae, was evaluated using the chinchilla animal model. The results showed that cefixime, administered in moderately low doses (8 mg/kg of body weight, two times per day), readily penetrated the chinchilla middle ear and rapidly sterilized the effusion. The data also suggest that the effusions were resolved more quickly in the cefixime-treated group compared with a group of animals treated with ampicillin or an untreated control group. No adverse side effects were noted in the cefixime-treated animals. The results of this study warrant the testing of cefixime for acute otitis media in the clinical setting.
A J Hotaling, and
W J Doyle, and
E I Cantekin
November 1980,
Southern medical journal,
A J Hotaling, and
W J Doyle, and
E I Cantekin
November 1988,
Archives of otolaryngology--head & neck surgery,
A J Hotaling, and
W J Doyle, and
E I Cantekin
December 1993,
The Pediatric infectious disease journal,
A J Hotaling, and
W J Doyle, and
E I Cantekin
November 2002,
Canadian family physician Medecin de famille canadien,
A J Hotaling, and
W J Doyle, and
E I Cantekin
June 1985,
British medical journal (Clinical research ed.),
A J Hotaling, and
W J Doyle, and
E I Cantekin
April 1985,
British medical journal (Clinical research ed.),
A J Hotaling, and
W J Doyle, and
E I Cantekin
April 2019,
Auris, nasus, larynx,
A J Hotaling, and
W J Doyle, and
E I Cantekin
January 1992,
The Journal of pediatrics,
A J Hotaling, and
W J Doyle, and
E I Cantekin
September 1949,
Archives of otolaryngology,
A J Hotaling, and
W J Doyle, and
E I Cantekin
March 2005,
Pediatric emergency care,
